热门资讯> 正文
阿斯利康-剥离entsis获得FDA批准用于首个针对不动杆菌的病原体靶向治疗
2023-05-24 23:49
- Innoviva Inc's (NASDAQ:INVA) affiliate Entasis Therapeutics Inc received FDA approval for Xacduro (sulbactam and durlobactam for injection), co-packaged as a treatment for hospital-acquired pneumonia.
- The approval covers patients 18 years and older for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by difficult-to-treat bacteria strains known as Acinetobacter baumannii-calcoaceticus complex.
- Innoviva acquired Entasis Therapeutics in May 2022 for $2.20 per share in cash.
- Also Read: FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections.
- Entasis was established in 2015 as a spin-off from AstraZeneca Plc (NASDAQ:AZN).
- Innoviva anticipates that Xacduro will be available to patients later this year.
- According to the World Health Organization, Acinetobacter species top the list of critical bacterial pathogens that pose the greatest threat to human health, the FDA wrote. A. baumannii can become highly resistant to multiple antibacterial drugs, with limited treatment options.
- In a Phase 3 ATTACK trial, the drug proved non-inferior to the last-resort antibiotic colistin in 28-day all-cause mortality, demonstrating a significant difference in clinical cure rates.
- Price Action: INVA shares are down 2.29% at $13.23 on the last check Wednesday.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
